- Home
- SCNX vs RNXT Comparison
SCNX vs RNXT Comparison
Compare SCNX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- RNXT
- Stock Information
- Founded
- SCNX 2010
- RNXT 2012
- Country
- SCNX United States
- RNXT United States
- Employees
- SCNX N/A
- RNXT N/A
- Industry
- SCNX Other Pharmaceuticals
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- RNXT Health Care
- Exchange
- SCNX Nasdaq
- RNXT Nasdaq
- Market Cap
- SCNX 33.6M
- RNXT 34.0M
- IPO Year
- SCNX 2020
- RNXT 2021
- Fundamental
- Price
- SCNX $1.24
- RNXT $1.02
- Analyst Decision
- SCNX
- RNXT Strong Buy
- Analyst Count
- SCNX 0
- RNXT 1
- Target Price
- SCNX N/A
- RNXT $9.00
- AVG Volume (30 Days)
- SCNX 2.8M
- RNXT 134.5K
- Earning Date
- SCNX 05-10-2025
- RNXT 05-09-2025
- Dividend Yield
- SCNX N/A
- RNXT N/A
- EPS Growth
- SCNX N/A
- RNXT N/A
- EPS
- SCNX 3.55
- RNXT N/A
- Revenue
- SCNX N/A
- RNXT N/A
- Revenue This Year
- SCNX $1,085.75
- RNXT N/A
- Revenue Next Year
- SCNX N/A
- RNXT N/A
- P/E Ratio
- SCNX $0.53
- RNXT N/A
- Revenue Growth
- SCNX 166.67
- RNXT N/A
- 52 Week Low
- SCNX $1.00
- RNXT $0.77
- 52 Week High
- SCNX $30.05
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- RNXT 46.22
- Support Level
- SCNX N/A
- RNXT $0.91
- Resistance Level
- SCNX N/A
- RNXT $1.03
- Average True Range (ATR)
- SCNX 0.00
- RNXT 0.07
- MACD
- SCNX 0.00
- RNXT 0.01
- Stochastic Oscillator
- SCNX 0.00
- RNXT 77.78
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.